{"id":1734,"date":"2026-10-19T10:24:20","date_gmt":"2026-10-19T08:24:20","guid":{"rendered":"https:\/\/5mn.ch\/?post_type=clinical_data&#038;p=1734"},"modified":"2026-10-19T11:10:00","modified_gmt":"2026-10-19T09:10:00","slug":"triglycerides-2026-10-19","status":"publish","type":"clinical_data","link":"https:\/\/5mn.ch\/de\/research\/clinical-data\/triglycerides-2026-10-19\/","title":{"rendered":"Triglyceride drugs: pancreatitis yes, heart no \u2014 19 October 2026"},"content":{"rendered":"\n<div class=\"db-brief\" lang=\"en\">\n<style>.db-brief .db-figures.db-wrap th,.db-brief .db-figures.db-wrap td{white-space:normal !important;text-align:left !important;overflow-wrap:break-word;hyphens:auto}.db-brief .db-timeline{margin:18px 0;overflow-x:auto;border:1px solid #e4e6e0;border-radius:10px;background:#fff;padding:8px 4px}.db-brief .db-timeline svg{display:block;width:100%;min-width:760px;height:auto}.db-brief .db-figures.db-wrap th[scope=\"row\"] span{font-weight:400;color:#5b6275;font-size:.9em}@media (max-width:767px){.db-brief .db-figures.db-wrap table{font-size:12px}.db-brief .db-figures.db-wrap th,.db-brief .db-figures.db-wrap td{padding:6px 5px}.db-brief .db-figures.db-wrap th[scope=\"row\"]{width:auto}.db-brief .db-figures.db-wrap thead th{font-size:10px;letter-spacing:0}}<\/style>\n<article class=\"db-item\" id=\"triglyceride-drugs-pancreatitis-vs-heart\">\n<p class=\"db-tags\"><span class=\"db-tag\">Sobi \u00b7 SOBI<\/span><span class=\"db-tag\">Arrowhead \u00b7 ARWR<\/span><span class=\"db-tag\">Novartis \u00b7 NOVN<\/span><span class=\"db-type\">Clinical data<\/span><\/p>\n<h4>Triglyceride drugs: they prevent pancreatitis, but heart benefit is still unproven<\/h4>\n<p>On 16 October 2026 the EU medicines committee backed Sobi&#8217;s Tryngolza (olezarsen) for adults with severe hypertriglyceridaemia (sHTG), very high blood fats. Six weeks earlier, Novartis&#8217;s pelacarsen failed to prevent heart attacks despite lowering Lp(a), another blood fat. Read together, a decade of trials shows a split: drugs that lower triglycerides prevent pancreatitis, but they have rarely prevented heart attacks or strokes.<\/p>\n<div class=\"db-figures db-wrap\"><table>\n<caption>FCS and sHTG \u00b7 main goal is the triglyceride cut, pancreatitis a key secondary<\/caption>\n<thead><tr><th scope=\"col\">Drug \u00b7 trial<\/th><th scope=\"col\">Primary endpoint<\/th><th scope=\"col\">Result<\/th><th scope=\"col\">Fewer pancreatitis?<\/th><\/tr><\/thead>\n<tbody>\n<tr class=\"db-up\"><th scope=\"row\">Olezarsen (Tryngolza) \u00b7 CORE \/ CORE2<br><span>sHTG<\/span><\/th><td>% change in TG at 6 months<\/td><td>\u201349% to \u201372% vs placebo; P&lt;0.001<\/td><td class=\"db-new\">Yes: \u201385% (rate ratio 0.15); 1 attack avoided per 20 treated, per 4 after a past attack<\/td><\/tr>\n<tr class=\"db-up\"><th scope=\"row\">Olezarsen \u00b7 Balance<br><span>FCS<\/span><\/th><td>% change in TG at 6 months<\/td><td>Significant, P=0.0009<\/td><td class=\"db-new\">Yes: 0 vs 11 attacks<\/td><\/tr>\n<tr class=\"db-up\"><th scope=\"row\">Plozasiran (Redemplo) \u00b7 PALISADE<br><span>FCS<\/span><\/th><td>Median % change in TG at 10 months<\/td><td>\u201380% vs \u201317% placebo<\/td><td class=\"db-new\">Yes: odds ratio 0.17, P=0.03<\/td><\/tr>\n<tr class=\"db-up\"><th scope=\"row\">Plozasiran \u00b7 SHASTA-3 \/ SHASTA-4<br><span>sHTG<\/span><\/th><td>% change in TG at 12 months<\/td><td>\u201379% \/ \u201381% vs placebo<\/td><td class=\"db-new\">Yes: \u201378% (pooled)<\/td><\/tr>\n<tr class=\"db-up\"><th scope=\"row\">Volanesorsen (Waylivra) \u00b7 APPROACH<br><span>FCS<\/span><\/th><td>% change in TG at 3 months<\/td><td>\u201377% vs +18% placebo<\/td><td class=\"db-new\">Yes: 1 vs 6* (P=0.019)<\/td><\/tr>\n<tr class=\"db-down\"><th scope=\"row\">Pradigastat (Novartis) \u00b7 Phase 3<br><span>FCS<\/span><\/th><td>% change in TG at 12 weeks<\/td><td>Not published; not filed<\/td><td>Not an endpoint<\/td><\/tr>\n<tr><th scope=\"row\">Glybera (uniQure) \u00b7 single-arm studies<br><span>LPL deficiency<\/span><\/th><td>Fat clearance after meals<\/td><td>EU approval 2012 (exceptional circumstances)<\/td><td>No randomised data<\/td><\/tr>\n<\/tbody><\/table>\n<p class=\"db-figures-note\">\u25b2 pancreatitis attacks reduced; \u25bc development failed. TG = triglycerides. FCS = familial chylomicronaemia syndrome, the rare inherited form; sHTG = severe hypertriglyceridaemia from any cause (US label TG \u2265500 mg\/dL; EU opinion \u2265880 mg\/dL, 10 mmol\/L). *Pooled APPROACH and COMPASS.<\/p><\/div>\n<div class=\"db-figures db-wrap\"><table>\n<caption>Heart-outcome trials \u00b7 main goal is fewer heart attacks, strokes and cardiovascular deaths<\/caption>\n<thead><tr><th scope=\"col\">Drug \u00b7 trial<\/th><th scope=\"col\">Patients<\/th><th scope=\"col\">Primary endpoint<\/th><th scope=\"col\">Fewer events?<\/th><\/tr><\/thead>\n<tbody>\n<tr class=\"db-up\"><th scope=\"row\">Icosapent ethyl (Vascepa, Amarin) \u00b7 REDUCE-IT<\/th><td>High TG, statins, n=8,179<\/td><td>5-part heart events<\/td><td class=\"db-new\">Yes: HR 0.75 (17.2% vs 22.0%)**<\/td><\/tr>\n<tr class=\"db-down\"><th scope=\"row\">Omega-3 acids (Epanova, AstraZeneca) \u00b7 STRENGTH<\/th><td>High TG, low HDL, n=13,078<\/td><td>5-part heart events<\/td><td>No: 12.0% vs 12.2%; stopped 2020<\/td><\/tr>\n<tr class=\"db-down\"><th scope=\"row\">Pemafibrate (Kowa) \u00b7 PROMINENT<\/th><td>Diabetes, high TG, n=10,497<\/td><td>Heart events<\/td><td>No: HR 1.03 (TG \u201326%)<\/td><\/tr>\n<tr class=\"db-down\"><th scope=\"row\">Fenofibrate \u00b7 FIELD<\/th><td>Diabetes, n=9,795<\/td><td>Coronary events<\/td><td>No: HR 0.89, not significant<\/td><\/tr>\n<tr class=\"db-down\"><th scope=\"row\">Pelacarsen (Novartis) \u00b7 Lp(a)HORIZON<\/th><td>High Lp(a), heart disease, n=8,323<\/td><td>4-part heart events<\/td><td>No: missed (Sep 2026)<\/td><\/tr>\n<tr><th scope=\"row\">Inclisiran (Leqvio, Novartis) \u00b7 ORION-4<\/th><td>Heart or vessel disease, n=16,124<\/td><td>4-part heart events<\/td><td>Pending: due Oct 2026; VICTORION-2P May 2027<\/td><\/tr>\n<\/tbody><\/table>\n<p class=\"db-figures-note\">**Debated: the mineral-oil placebo may have raised risk in the control group. Leqvio lowers LDL cholesterol, the one blood fat where lowering is proven to cut heart events; it was approved on its LDL effect.<\/p><\/div>\n<div class=\"db-timeline\"><svg viewBox=\"0 0 960 458\" width=\"100%\" role=\"img\" aria-labelledby=\"tg-tl-t\" font-family=\"inherit\" font-size=\"13\"><title id=\"tg-tl-t\">Timeline of triglyceride and lipid drugs, 2012 to 2027<\/title><circle cx=\"150\" cy=\"18\" r=\"6\" fill=\"#2f6f4c\"><\/circle><text x=\"162\" y=\"22\" fill=\"#5b6275\">approval or positive result<\/text><circle cx=\"350\" cy=\"18\" r=\"6\" fill=\"#a3322b\"><\/circle><text x=\"362\" y=\"22\" fill=\"#5b6275\">failure, rejection or lapse<\/text><circle cx=\"550\" cy=\"18\" r=\"6\" fill=\"#fff\" stroke=\"#1b2036\" stroke-width=\"2\"><\/circle><text x=\"562\" y=\"22\" fill=\"#5b6275\">expected<\/text><rect x=\"680\" y=\"13\" width=\"26\" height=\"10\" rx=\"5\" fill=\"#2f6f4c\" opacity=\".25\"><\/rect><text x=\"714\" y=\"22\" fill=\"#5b6275\">on the market<\/text><line x1=\"150.0\" y1=\"44\" x2=\"150.0\" y2=\"424\" stroke=\"#e4e6e0\"><\/line><text x=\"150.0\" y=\"442\" text-anchor=\"middle\" fill=\"#5b6275\">2012<\/text><line x1=\"247.5\" y1=\"44\" x2=\"247.5\" y2=\"424\" stroke=\"#e4e6e0\"><\/line><text x=\"247.5\" y=\"442\" text-anchor=\"middle\" fill=\"#5b6275\">2014<\/text><line x1=\"345.0\" y1=\"44\" x2=\"345.0\" y2=\"424\" stroke=\"#e4e6e0\"><\/line><text x=\"345.0\" y=\"442\" text-anchor=\"middle\" fill=\"#5b6275\">2016<\/text><line x1=\"442.5\" y1=\"44\" x2=\"442.5\" y2=\"424\" stroke=\"#e4e6e0\"><\/line><text x=\"442.5\" y=\"442\" text-anchor=\"middle\" fill=\"#5b6275\">2018<\/text><line x1=\"540.0\" y1=\"44\" x2=\"540.0\" y2=\"424\" stroke=\"#e4e6e0\"><\/line><text x=\"540.0\" y=\"442\" text-anchor=\"middle\" fill=\"#5b6275\">2020<\/text><line x1=\"637.5\" y1=\"44\" x2=\"637.5\" y2=\"424\" stroke=\"#e4e6e0\"><\/line><text x=\"637.5\" y=\"442\" text-anchor=\"middle\" fill=\"#5b6275\">2022<\/text><line x1=\"735.0\" y1=\"44\" x2=\"735.0\" y2=\"424\" stroke=\"#e4e6e0\"><\/line><text x=\"735.0\" y=\"442\" text-anchor=\"middle\" fill=\"#5b6275\">2024<\/text><line x1=\"832.5\" y1=\"44\" x2=\"832.5\" y2=\"424\" stroke=\"#e4e6e0\"><\/line><text x=\"832.5\" y=\"442\" text-anchor=\"middle\" fill=\"#5b6275\">2026<\/text><line x1=\"930.0\" y1=\"44\" x2=\"930.0\" y2=\"424\" stroke=\"#e4e6e0\"><\/line><text x=\"930.0\" y=\"442\" text-anchor=\"middle\" fill=\"#5b6275\">2028<\/text><text x=\"10\" y=\"66\" font-weight=\"600\" fill=\"#1b2036\">uniQure<\/text><text x=\"10\" y=\"81\" font-size=\"11\" fill=\"#5b6275\">Glybera (gene therapy)<\/text><line x1=\"150\" y1=\"68\" x2=\"930\" y2=\"68\" stroke=\"#e4e6e0\" stroke-dasharray=\"2 4\"><\/line><text x=\"10\" y=\"112\" font-weight=\"600\" fill=\"#1b2036\">Novartis<\/text><text x=\"10\" y=\"127\" font-size=\"11\" fill=\"#5b6275\">pradigastat \u00b7 pelacarsen \u00b7 Leqvio<\/text><line x1=\"150\" y1=\"114\" x2=\"930\" y2=\"114\" stroke=\"#e4e6e0\" stroke-dasharray=\"2 4\"><\/line><text x=\"10\" y=\"158\" font-weight=\"600\" fill=\"#1b2036\">Akcea \/ Ionis<\/text><text x=\"10\" y=\"173\" font-size=\"11\" fill=\"#5b6275\">volanesorsen (Waylivra)<\/text><line x1=\"150\" y1=\"160\" x2=\"930\" y2=\"160\" stroke=\"#e4e6e0\" stroke-dasharray=\"2 4\"><\/line><text x=\"10\" y=\"204\" font-weight=\"600\" fill=\"#1b2036\">Ionis \/ Sobi<\/text><text x=\"10\" y=\"219\" font-size=\"11\" fill=\"#5b6275\">olezarsen (Tryngolza)<\/text><line x1=\"150\" y1=\"206\" x2=\"930\" y2=\"206\" stroke=\"#e4e6e0\" stroke-dasharray=\"2 4\"><\/line><text x=\"10\" y=\"250\" font-weight=\"600\" fill=\"#1b2036\">Arrowhead<\/text><text x=\"10\" y=\"265\" font-size=\"11\" fill=\"#5b6275\">plozasiran (Redemplo)<\/text><line x1=\"150\" y1=\"252\" x2=\"930\" y2=\"252\" stroke=\"#e4e6e0\" stroke-dasharray=\"2 4\"><\/line><text x=\"10\" y=\"296\" font-weight=\"600\" fill=\"#1b2036\">Amarin<\/text><text x=\"10\" y=\"311\" font-size=\"11\" fill=\"#5b6275\">icosapent ethyl (Vascepa)<\/text><line x1=\"150\" y1=\"298\" x2=\"930\" y2=\"298\" stroke=\"#e4e6e0\" stroke-dasharray=\"2 4\"><\/line><text x=\"10\" y=\"342\" font-weight=\"600\" fill=\"#1b2036\">AstraZeneca<\/text><text x=\"10\" y=\"357\" font-size=\"11\" fill=\"#5b6275\">omega-3 acids (Epanova)<\/text><line x1=\"150\" y1=\"344\" x2=\"930\" y2=\"344\" stroke=\"#e4e6e0\" stroke-dasharray=\"2 4\"><\/line><text x=\"10\" y=\"388\" font-weight=\"600\" fill=\"#1b2036\">Kowa<\/text><text x=\"10\" y=\"403\" font-size=\"11\" fill=\"#5b6275\">pemafibrate<\/text><line x1=\"150\" y1=\"390\" x2=\"930\" y2=\"390\" stroke=\"#e4e6e0\" stroke-dasharray=\"2 4\"><\/line><rect x=\"189.0\" y=\"62\" width=\"243.8\" height=\"12\" rx=\"6\" fill=\"#2f6f4c\" opacity=\".25\"><\/rect><circle cx=\"189.0\" cy=\"68\" r=\"6\" fill=\"#2f6f4c\"><\/circle><text x=\"198.0\" y=\"60\" text-anchor=\"start\" font-size=\"11.5\" fill=\"#1b2036\">EU approval (LPLD) 2012<\/text><circle cx=\"432.7\" cy=\"68\" r=\"6\" fill=\"#a3322b\"><\/circle><text x=\"441.7\" y=\"60\" text-anchor=\"start\" font-size=\"11.5\" fill=\"#1b2036\">licence lapses 2017<\/text><circle cx=\"296.2\" cy=\"114\" r=\"6\" fill=\"#a3322b\"><\/circle><text x=\"305.2\" y=\"106\" text-anchor=\"start\" font-size=\"11.5\" fill=\"#1b2036\">pradigastat dropped 2015<\/text><circle cx=\"865.2\" cy=\"114\" r=\"6\" fill=\"#a3322b\"><\/circle><text x=\"856.2\" y=\"106\" text-anchor=\"end\" font-size=\"11.5\" fill=\"#1b2036\">pelacarsen misses Sep 2026<\/text><circle cx=\"900.8\" cy=\"114\" r=\"6\" fill=\"#fff\" stroke=\"#1b2036\" stroke-width=\"2\"><\/circle><circle cx=\"900.8\" cy=\"114\" r=\"6\" fill=\"#fff\" stroke=\"#1b2036\" stroke-width=\"2\"><\/circle><text x=\"891.8\" y=\"132\" text-anchor=\"end\" font-size=\"11.5\" fill=\"#1b2036\">Leqvio outcomes 2026\u201327<\/text><circle cx=\"474.2\" cy=\"160\" r=\"6\" fill=\"#a3322b\"><\/circle><text x=\"465.2\" y=\"152\" text-anchor=\"end\" font-size=\"11.5\" fill=\"#1b2036\">US rejection 2018<\/text><rect x=\"507.3\" y=\"154\" width=\"422.7\" height=\"12\" rx=\"6\" fill=\"#2f6f4c\" opacity=\".25\"><\/rect><circle cx=\"507.3\" cy=\"160\" r=\"6\" fill=\"#2f6f4c\"><\/circle><text x=\"516.3\" y=\"152\" text-anchor=\"start\" font-size=\"11.5\" fill=\"#1b2036\">EU conditional approval (FCS) 2019<\/text><rect x=\"781.3\" y=\"200\" width=\"148.7\" height=\"12\" rx=\"6\" fill=\"#2f6f4c\" opacity=\".25\"><\/rect><circle cx=\"781.3\" cy=\"206\" r=\"6\" fill=\"#2f6f4c\"><\/circle><text x=\"772.3\" y=\"198\" text-anchor=\"end\" font-size=\"11.5\" fill=\"#1b2036\">US FCS Dec 2024<\/text><circle cx=\"818.9\" cy=\"206\" r=\"6\" fill=\"#2f6f4c\"><\/circle><circle cx=\"844.7\" cy=\"206\" r=\"6\" fill=\"#5b6275\"><\/circle><circle cx=\"855.4\" cy=\"206\" r=\"6\" fill=\"#2f6f4c\"><\/circle><circle cx=\"871.5\" cy=\"206\" r=\"6\" fill=\"#2f6f4c\"><\/circle><text x=\"925.1\" y=\"228\" text-anchor=\"end\" font-size=\"11.5\" fill=\"#1b2036\">EU FCS 9\/25 \u00b7 price cut 93% 4\/26 \u00b7 US sHTG 6\/26 \u00b7 EU sHTG opinion 10\/26<\/text><rect x=\"826.2\" y=\"246\" width=\"103.8\" height=\"12\" rx=\"6\" fill=\"#2f6f4c\" opacity=\".25\"><\/rect><circle cx=\"826.2\" cy=\"252\" r=\"6\" fill=\"#2f6f4c\"><\/circle><text x=\"817.2\" y=\"244\" text-anchor=\"end\" font-size=\"11.5\" fill=\"#1b2036\">US FCS Nov 2025<\/text><circle cx=\"855.4\" cy=\"252\" r=\"6\" fill=\"#2f6f4c\"><\/circle><text x=\"864.4\" y=\"244\" text-anchor=\"start\" font-size=\"11.5\" fill=\"#1b2036\">EU FCS 6\/26<\/text><circle cx=\"878.8\" cy=\"252\" r=\"6\" fill=\"#fff\" stroke=\"#1b2036\" stroke-width=\"2\"><\/circle><text x=\"925.1\" y=\"274\" text-anchor=\"end\" font-size=\"11.5\" fill=\"#1b2036\">US sHTG filing planned Q4 2026<\/text><circle cx=\"483.9\" cy=\"298\" r=\"6\" fill=\"#2f6f4c\"><\/circle><text x=\"492.9\" y=\"290\" text-anchor=\"start\" font-size=\"11.5\" fill=\"#1b2036\">REDUCE-IT: heart events \u201325% (2018)<\/text><circle cx=\"541.9\" cy=\"344\" r=\"6\" fill=\"#a3322b\"><\/circle><text x=\"550.9\" y=\"336\" text-anchor=\"start\" font-size=\"11.5\" fill=\"#1b2036\">STRENGTH stopped for futility (2020)<\/text><circle cx=\"678.9\" cy=\"390\" r=\"6\" fill=\"#a3322b\"><\/circle><text x=\"687.9\" y=\"382\" text-anchor=\"start\" font-size=\"11.5\" fill=\"#1b2036\">PROMINENT: no heart benefit (2022)<\/text><\/svg><\/div>\n<div class=\"db-figures db-wrap\"><table>\n<caption>On the market in FCS and sHTG \u00b7 sales so far<\/caption>\n<thead><tr><th scope=\"col\">Product<\/th><th scope=\"col\">Approved for<\/th><th scope=\"col\">Reported sales<\/th><th scope=\"col\">Company ambition<\/th><th scope=\"col\">Market peak estimate<\/th><\/tr><\/thead>\n<tbody>\n<tr><th scope=\"row\">Tryngolza US (Ionis)<\/th><td>FCS 12\/24; sHTG 6\/26 (US)<\/td><td>FY 25: USD 105M; H1 26: USD 32M (Q2 26: USD 5M, after price cut); FY 26 guide: USD 100\u2013110M<\/td><td class=\"db-new\">Peak above USD 3B<\/td><td>About USD 3B<\/td><\/tr>\n<tr><th scope=\"row\">Tryngolza ex-US (Sobi)<\/th><td>FCS 9\/25; sHTG opinion 10\/26 (EU)<\/td><td>SEK 47M in Q2 26<\/td><td class=\"db-new\">Peak above SEK 10B<\/td><td>Not published<\/td><\/tr>\n<tr><th scope=\"row\">Redemplo (Arrowhead)<\/th><td>FCS: US 11\/25, EU 6\/26<\/td><td>Not reported separately<\/td><td>Not given<\/td><td>Not published<\/td><\/tr>\n<tr><th scope=\"row\">Waylivra (Ionis; Sobi in Europe)<\/th><td>FCS: EU 5\/19 (conditional)<\/td><td>Not reported separately<\/td><td>\u2014<\/td><td>\u2014<\/td><\/tr>\n<\/tbody><\/table>\n<p class=\"db-figures-note\">US list prices: Tryngolza USD 40,000 a year since April 2026 (from USD 595,000); Redemplo USD 60,000 a year. Sobi counts about 1 million sHTG patients in Europe with TG above 880 mg\/dL, about 300,000 of them not controlled by current treatment; Ionis targets about 3 million US patients, 1 million at high risk.<\/p><\/div>\n<details class=\"db-plain\">\n<summary>In plain words<\/summary>\n<p><strong>What happened.<\/strong> New injections can cut triglycerides, a type of blood fat, by more than half. In people with very high levels, they also prevent attacks of pancreatitis, a painful and sometimes deadly inflammation of the pancreas. The EU is about to approve one of them, Sobi&#8217;s Tryngolza, for a much larger group of patients.<\/p>\n<p><strong>Why it matters.<\/strong> Lowering blood fats other than LDL cholesterol has rarely prevented heart attacks. Novartis&#8217;s recent failure with a drug against Lp(a), another blood fat, added to that record. So these drugs are worth what they prevent in pancreatitis, a rarer event than heart attacks, and health systems will judge their price on that.<\/p>\n<\/details>\n<p class=\"db-context\"><span class=\"db-context-label\">The key question<\/span> Can the price hold when the value rests on pancreatitis alone? Neither olezarsen nor plozasiran has reported a heart-outcome trial, and STRENGTH, PROMINENT, FIELD and now Lp(a)HORIZON give little reason to expect a heart benefit. In CORE\/CORE2, 20 patients had to be treated for a year to avoid one attack, 4 among those who had already had one: at the US list price of USD 40,000 a year, about est. USD 0.8M and est. USD 0.16M per attack avoided, before rebates and hospital savings. Ionis chose volume over price: it cut the list price by 93% in April 2026 and only then raised its peak-sales guidance to above USD 3B (from above USD 2B in January), which at list price means about est. 75,000 patients, some 7.5% of the 1 million high-risk US patients it targets. Outside the US the FCS price is still at rare-disease level: Outside the US the FCS price is still at rare-disease level: in Germany, Sobi\u2019s monthly 80 mg pen is listed at EUR 29,800, about calc. EUR 358,000 a year against USD 40,000 in the US; in Canada, where Ionis keeps the rights, the submitted price of CAD 492,000 a year was judged cost-effective only with a cut of 75% or more (CAD 3.0M per QALY gained in the base case). As most European countries set one price per medicine across its uses, the sHTG launch in 2027 will likely force a similar reset in Europe. Sobi\u2019s Q3 26 report on 27 October is the first chance to hear how it plans to price the wider label.<\/p><\/article>\n<p class=\"db-disclosure\" style=\"margin:18px 0 0;padding-top:12px;border-top:1px solid #dfe6e1;font-size:14px;line-height:1.5;color:#5b6470\">Disclosures: figures marked calc. or est. are 5mn\u2019s own. 5mn does not cover companies it advises, and 5mn and its analysts hold no positions in the company covered. This note is general information, not investment advice or a recommendation to buy, sell or hold any security. Full terms: <a href=\"\/disclaimer\/\" style=\"color:#2f6f4c;text-decoration:underline;text-underline-offset:3px\">5mn.ch\/disclaimer<\/a>.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The new RNA drugs that cut triglycerides prevent pancreatitis, but lowering triglycerides or Lp(a) has rarely cut heart attacks, which puts the price question at the centre.<\/p>","protected":false},"featured_media":0,"template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"class_list":["post-1734","clinical_data","type-clinical_data","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Triglyceride drugs: pancreatitis yes, heart no \u2014 19 October 2026 - 5mn<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/5mn.ch\/de\/research\/clinical-data\/triglycerides-2026-10-19\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Triglyceride drugs: pancreatitis yes, heart no \u2014 19 October 2026 - 5mn\" \/>\n<meta property=\"og:description\" content=\"The new RNA drugs that cut triglycerides prevent pancreatitis, but lowering triglycerides or Lp(a) has rarely cut heart attacks, which puts the price question at the centre.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/5mn.ch\/de\/research\/clinical-data\/triglycerides-2026-10-19\/\" \/>\n<meta property=\"og:site_name\" content=\"5mn\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-19T09:10:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"6\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/5mn.ch\\\/research\\\/clinical-data\\\/triglycerides-2026-10-19\\\/\",\"url\":\"https:\\\/\\\/5mn.ch\\\/research\\\/clinical-data\\\/triglycerides-2026-10-19\\\/\",\"name\":\"Triglyceride drugs: pancreatitis yes, heart no \u2014 19 October 2026 - 5mn\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/5mn.ch\\\/#website\"},\"datePublished\":\"2026-10-19T08:24:20+00:00\",\"dateModified\":\"2026-10-19T09:10:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/5mn.ch\\\/research\\\/clinical-data\\\/triglycerides-2026-10-19\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/5mn.ch\\\/research\\\/clinical-data\\\/triglycerides-2026-10-19\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/5mn.ch\\\/research\\\/clinical-data\\\/triglycerides-2026-10-19\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/5mn.ch\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Triglyceride drugs: pancreatitis yes, heart no \u2014 19 October 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/5mn.ch\\\/#website\",\"url\":\"https:\\\/\\\/5mn.ch\\\/\",\"name\":\"5mn\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/5mn.ch\\\/#organization\"},\"alternateName\":\"5mn.ch\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/5mn.ch\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/5mn.ch\\\/#organization\",\"name\":\"5mn\",\"alternateName\":\"5mn.ch\",\"url\":\"https:\\\/\\\/5mn.ch\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/5mn.ch\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/5mn.ch\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/5mn-icon-512_1.png\",\"contentUrl\":\"https:\\\/\\\/5mn.ch\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/5mn-icon-512_1.png\",\"width\":512,\"height\":512,\"caption\":\"5mn\"},\"image\":{\"@id\":\"https:\\\/\\\/5mn.ch\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Triglyceride drugs: pancreatitis yes, heart no \u2014 19 October 2026 - 5mn","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/5mn.ch\/de\/research\/clinical-data\/triglycerides-2026-10-19\/","og_locale":"de_DE","og_type":"article","og_title":"Triglyceride drugs: pancreatitis yes, heart no \u2014 19 October 2026 - 5mn","og_description":"The new RNA drugs that cut triglycerides prevent pancreatitis, but lowering triglycerides or Lp(a) has rarely cut heart attacks, which puts the price question at the centre.","og_url":"https:\/\/5mn.ch\/de\/research\/clinical-data\/triglycerides-2026-10-19\/","og_site_name":"5mn","article_modified_time":"2026-10-19T09:10:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"6\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/5mn.ch\/research\/clinical-data\/triglycerides-2026-10-19\/","url":"https:\/\/5mn.ch\/research\/clinical-data\/triglycerides-2026-10-19\/","name":"Triglyceride drugs: pancreatitis yes, heart no \u2014 19 October 2026 - 5mn","isPartOf":{"@id":"https:\/\/5mn.ch\/#website"},"datePublished":"2026-10-19T08:24:20+00:00","dateModified":"2026-10-19T09:10:00+00:00","breadcrumb":{"@id":"https:\/\/5mn.ch\/research\/clinical-data\/triglycerides-2026-10-19\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/5mn.ch\/research\/clinical-data\/triglycerides-2026-10-19\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/5mn.ch\/research\/clinical-data\/triglycerides-2026-10-19\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/5mn.ch\/"},{"@type":"ListItem","position":2,"name":"Triglyceride drugs: pancreatitis yes, heart no \u2014 19 October 2026"}]},{"@type":"WebSite","@id":"https:\/\/5mn.ch\/#website","url":"https:\/\/5mn.ch\/","name":"5mn","description":"","publisher":{"@id":"https:\/\/5mn.ch\/#organization"},"alternateName":"5mn.ch","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/5mn.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/5mn.ch\/#organization","name":"5mn","alternateName":"5mn.ch","url":"https:\/\/5mn.ch\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/5mn.ch\/#\/schema\/logo\/image\/","url":"https:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/5mn-icon-512_1.png","contentUrl":"https:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/5mn-icon-512_1.png","width":512,"height":512,"caption":"5mn"},"image":{"@id":"https:\/\/5mn.ch\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/5mn.ch\/de\/wp-json\/wp\/v2\/clinical_data\/1734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/5mn.ch\/de\/wp-json\/wp\/v2\/clinical_data"}],"about":[{"href":"https:\/\/5mn.ch\/de\/wp-json\/wp\/v2\/types\/clinical_data"}],"wp:attachment":[{"href":"https:\/\/5mn.ch\/de\/wp-json\/wp\/v2\/media?parent=1734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}